Clinical Trials Using Asparaginase Erwinia chrysanthemi

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Asparaginase Erwinia chrysanthemi. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome

    This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Response-based chemotherapy separates patients into different risk groups and treats them according to how they respond to the first course of treatment (Induction I). Response-based treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome while reducing the side effects.
    Location: 142 locations

  • A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

    This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
    Location: 12 locations

  • Azacitidine or Decitabine in Epigenetic Priming in Patients with Newly Diagnosed Acute Myeloid Leukemia

    This randomized phase II trial studies how well azacitidine or decitabine work in epigenetic priming in patients with newly diagnosed acute myeloid leukemia. Azacitidine and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Panobinostat, Bortezomib, and Vincristine Sulfate Liposome with Re-induction Therapy in Treating Younger Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma

    This phase II trial studies how well panobinostat, bortezomib, and vincristine sulfate liposome and re-induction therapy (strong chemotherapy) work in treating younger patients with T-cell acute lymphoblastic leukemia or lymphoma that has returned (relapsed) or does not respond to treatment (refractory). Panobinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitoxantrone hydrochloride, pegaspargase, dexamethasone, cytarabine, vincristine sulfate liposome, methotrexate, mercaptopurine, nelarabine, cyclophosphamide, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving panobinostat, bortezomib, and vincristine sulfate liposome together with re-induction therapy may kill more cancer cells.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee

  • Fludarabine Phosphate, Cytarabine, and Asparaginase Erwinia Chrysanthemi in Treating Patients with Relapsed or Refractory Hematologic Malignancies

    This phase II trial studies how well fludarabine phosphate, cytarabine, and asparaginase Erwinia chrysanthemi work in treating patients with hematologic malignancies. Drugs used in chemotherapy, such as fludarabine phosphate and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Biological therapies, such as asparaginase Erwinia chrysanthemi, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Giving fludarabine phosphate, cytarabine, and asparaginase Erwinia chrysanthemi may work better in treating patients with relapsed or refractory hematologic malignancies.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Calaspargase Pegol or Pegaspargase in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    This partially randomized phase II trial studies how well calaspargase pegol or pegaspargase works in treating younger patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as calaspargase pegol and pegaspargase, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether calaspargase pegol or pegaspargase works better in treating patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Location: 11 locations